# GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.

> **NCT00439920** · PHASE2 · UNKNOWN · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto**

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** High-dose anthracycline

## Key facts

- **NCT ID:** NCT00439920
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1996-10
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** — (—)
- **Last updated:** 2018-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00439920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00439920, "GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00439920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*